{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pauthner MG"],"funding":["Translational Virology Core at the UC San Diego Center for AIDS Research","IGM Genomics Center, University of California, San Diego, La Jolla, California","NIAID NIH HHS","Achievement Rewards for College Scientists Foundation","National Institutes of Health","NIH","NIAID","Canada Research Chair on Retroviral Entry","CIHR","CIHR Fellowship","International AIDS Vaccine Initiative","National Institute of Allergy and Infectious Diseases","Bill & Melinda Gates Foundation","CIHR foundation","NIH HHS"],"pagination":["241-252.e6"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6335502"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["50(1)"],"pubmed_abstract":["Passive administration of HIV neutralizing antibodies (nAbs) can protect macaques from hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge. However, conditions for nAb-mediated protection after vaccination have not been established. Here, we selected groups of 6 rhesus macaques with either high or low serum nAb titers from a total of 78 animals immunized with recombinant native-like (SOSIP) Env trimers. Repeat intrarectal challenge with homologous tier 2 SHIVBG505 led to rapid infection in unimmunized and low-titer animals. High-titer animals, however, demonstrated protection that was gradually lost as nAb titers waned over time. An autologous serum ID50 nAb titer of ∼1:500 afforded more than 90% protection from medium-dose SHIV infection. In contrast,"],"journal":["Immunity"],"pubmed_title":["Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers."],"pmcid":["PMC6335502"],"funding_grant_id":["UM1AI068618","352417","AI121135","R01 AI095098","AI126603","RCHS0235","R01 AI098485","R01 AI136621","UM1 AI068618","R01 AI131331","OPP1145046","AI136621","U19 AI128751","R01 AI121135","P30 AI036214","R00 AI120851","R00AI120851","F31 AI131873","UM1 AI126603","Al131873","AI124377","OPP1084519","UM1 AI124377","UM1AI100663","OD011106","P01 AI131251","AI128751","UM1 AI100663","P51 OD011106"],"pubmed_authors":["Irvine DJ","Evans DT","Bastidas R","Havenar-Daughton C","Reiss SM","von Bredow B","Burton DR","Shaw GM","Finzi A","Crotty S","Wyatt RT","Kulp DW","Nogal B","Ward AB","Schief WR","Cottrell CA","Lee JH","Li H","Sanders RW","Tokatlian T","Butera ST","Barouch DH","Bianchi M","Wilson IA","Prevost J","Hangartner L","Pauthner MG","Murrell B","Abbink P","Nkolola JP","Nedellec R"],"additional_accession":[]},"is_claimable":false,"name":"Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers.","description":"Passive administration of HIV neutralizing antibodies (nAbs) can protect macaques from hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge. However, conditions for nAb-mediated protection after vaccination have not been established. Here, we selected groups of 6 rhesus macaques with either high or low serum nAb titers from a total of 78 animals immunized with recombinant native-like (SOSIP) Env trimers. Repeat intrarectal challenge with homologous tier 2 SHIVBG505 led to rapid infection in unimmunized and low-titer animals. High-titer animals, however, demonstrated protection that was gradually lost as nAb titers waned over time. An autologous serum ID50 nAb titer of ∼1:500 afforded more than 90% protection from medium-dose SHIV infection. In contrast,","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jan","modification":"2025-04-26T07:05:48.328Z","creation":"2019-03-26T22:38:51Z"},"accession":"S-EPMC6335502","cross_references":{"pubmed":["30552025"],"doi":["10.1016/j.immuni.2018.11.011"]}}